Kaunas-based medical technology company BrachyDOSE has secured €554,000 in funding to conduct clinical testing of its radiation dose measurement system used in cancer treatment. The round was led by Coinvest Capital, contributing €300,000, with additional investment from BSV Ventures, as well as business angel groups LitBAN and EstBAN. BrachyDOSE develops a combined hardware–software solution designed to measure and predict radiation exposure during radiotherapy. The investment will be used to complete CE and MDR certification, which are required for medical device commercialization in the European Union. The company has previously worked with hospitals in Lithuania to validate its technology in clinical settings.
BrachyDOSE develops a radiation dose measurement system for use in cancer radiotherapy. The company’s solution integrates hardware sensors with predictive software to provide real-time data on radiation exposure during treatment. The technology is designed to support clinical decision-making and reduce the risk of radiation-related injuries. BrachyDOSE collaborates with hospitals and oncology centers to validate its device in clinical settings and is currently working toward regulatory certification for market entry in the European Union.
“We are grateful to the venture funds and angel investors who have supported us on our journey. This investment is a major boost that gives the BrachyDOSE team the opportunity to pursue our goal of helping cancer patients avoid the side effects of radiotherapy, while enabling hospitals and doctors to significantly improve the quality of cancer treatment,” said Neringa Šeperienė, founder and CEO of BrachyDOSE. “Once we obtain CE/MDR certification, we will be able to offer our product to both Lithuanian and international markets.”
Coinvest Capital contributed €300,000 as the lead investor in this round.
“Lithuania is recognised as one of the leading centres for training oncology specialists and scientists. We have modern infrastructure and decades of experience, yet Lithuanian-developed tools and technologies remain limited in this highly dynamic field. BrachyDOSE stands out for its versatility and broad applicability – the technology can be used in any oncology hospital worldwide. This is encouraging news for investors, but more importantly, it may be good news for cancer patients and oncology professionals alike,” said Viktorija Trimbel, Managing Director of Coinvest Capital.
Sandra Golbreich, Partner at BSV Ventures, commented: “Radiotherapy is a cornerstone of cancer treatment, but until now, doctors have had to rely on approximations of dose delivery, which can lead to unwanted side effects for patients. BrachyDOSE’s data-driven solution introduces a new level of precision that can significantly reduce these side effects. It’s a breakthrough for both patients and clinicians. As early supporters of BrachyDOSE, we’ve directly seen Neringa and her team’s unique expertise and strong commitment to improving patient outcomes. We are proud to continue supporting them and are excited to co-lead this round to help bring such an innovative solution to hospitals worldwide.”
BrachyDOSE is a patient-centric, data-driven measurement tool that helps doctors’ to prevent up to 100% of treatment-caused injuries in radiotherapy procedures. The solution is hardware and software combined.
The hardware includes a sensor and a scanner used to retrieve the data, while the software uses an injury prediction algorithm to provide decision support for a doctor. BrachyDOSE enables to save hospital costs, makes radiotherapy more efficient and most importantly helps cancer patients to recover faster.
The company has already collaborated with the National Cancer Centre of Vilnius University Hospital Santaros Clinics and the Oncology Hospital of the Lithuanian University of Health Sciences.
“Our approach is based on the belief that knowledge only creates value when it is applied. That’s why we want to share our competences and knowledge – to make the work of hospitals and doctors easier. Our team includes experts in medical device engineering, data analytics, and medical physics. We are joined by medical oncologists who work directly with patients in hospitals. Soon, we will be recruiting a medical device salesperson,” said N. Šeperienė.
Šeperienė holds degrees in applied physics and medical physics and earned a PhD in materials engineering from Kaunas University of Technology.
Click to read more funding news.
Read the orginal article: https://arcticstartup.com/brachydose-raises-e554k/
